Long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only.
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic ...
ascopubs.org › doi › JCO.2010.32.7312
Long-term outcome with respect to progression-free survival, overall survival, and relapse rate is superior after auto-allo compared with auto only.
Jun 20, 2013 · Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome ...
People also ask
What is the difference between autologous stem cell transplant and allogeneic stem cell transplant?
The stem cells in autologous transplants come from the same person who will get the transplant, so the patient is their own donor. Allogeneic: 'Allo' means other. The stem cells in allogeneic transplants are from a person other than the patient, either a matched related or unrelated donor.
What is the life expectancy after autologous stem cell transplant?
The median follow-up after transplantation in surviving members of the study cohort was 13.1 years (range, 5.0 to 36.1 years), and their median attained age at analysis was 46 years (range, 6 to 80 years).
What is the life expectancy after stem cell transplant for myeloma?
Conditional on surviving the first 2 to 5 years after stem cell transplantation, the 10-year overall survival approaches 80 percent, so as long as symptoms are managed, and your immune system stays functioning and healthy; long-term survival is possible and common!
Which is better autologous or allogeneic?
Autologous transplants have a lower risk of life-threatening complications; there is no risk of GVHD and no need for immunosuppressive therapy to prevent GVHD and graft rejection. Immune reconstitution is more rapid than after an allogeneic transplant and there is a lower risk of opportunistic infections.
Long-term follow-up of auto-auto versus auto-allo in newly diagnosed multiple myeloma patients confirms significant and durable reduction in risk of relapse.
Oct 18, 2023 · In comparison to tandem-auto-SCT, patients assigned to auto-allo-SCT exhibited a higher risk of transplant-related mortality (TRM) (11.9% vs.
Feb 1, 2019 · Our study showed that tandem autologous/minimal intensity allogeneic HCT for MM was safe and characterized by low acute and long-term toxicities.
Oct 25, 2017 · We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic ...
Nov 20, 2009 · Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning (RIC) is a controversial treatment in multiple myeloma.
Jan 4, 2013 · The Intergroupe Francophone du Myelome (IFM) demonstrated that tandem auto-auto HCT improves overall survival (OS) among patients with myeloma, ...
Feb 1, 2019 · Our data suggest that allo-SCT may enable long-term survival and a potential cure in a carefully selected subgroup of MM patients with tolerable toxicity.